Skip to main content
Erschienen in: Journal of Neurology 12/2021

Open Access 22.05.2021 | COVID-19 | Letter to the Editors

Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis

verfasst von: Tilmann Graf, Thomas Thiele, Randolf Klingebiel, Andreas Greinacher, Wolf-Rüdiger Schäbitz, Isabell Greeve

Erschienen in: Journal of Neurology | Ausgabe 12/2021

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Dear Sirs,
Here, we report a case of a 29-year-old male public health care professional, vaccinated with the recombinant adenoviral vector encoding the spike protein antigen of SARS-CoV-2 (ChAdOx1 nCov-19, AstraZeneca) on the 29th of March (day 1). Nine days later, he developed headache and abdominal pain, on day 12 emesis and abdominal cramps. On day 14, he was urgently admitted to a hospital due to severe headache and hematemesis. Upon admission, thrombocytopenia of 32/nL was detected. Gastroscopy showed diffuse mucosal bleeding. On MR imaging of the brain, a complete thrombosis of the left transverse and sigmoid sinus down to the left proximal jugular vein was demonstrated (Fig. 1a). The patient was immediately transferred to the Department of Neurology in our hospital. He had no neurological deficits at that time point and the MR imaging showed no involvement of the parenchyma and no bleeding due to the congestion of the sinus veins. An abdominal CT angiography revealed extensive thrombosis of the mesenteric and portal vein, explaining the profuse bleeding of the stomach. The novel vaccine-induced immune thrombotic thrombocytopenia (VITT), first described in March 2021, was suspected in this otherwise healthy young man not been exposed to heparin before [1, 2]. To inactivate the suspected pathogenic platelet factor-4 (PF4)-heparin antibodies through Fc receptor blocking, treatment with high-dose immunoglobulins (IVIG) at a dose of 1 g/kg body weight on day 1 and day 2 was started [3, 4]. During the first 24 h, the platelet count raised only marginally, but after 48 h, platelet count improved to 98/nl (Fig. 2). The severe multilocular thrombosis was treated with non-heparin-based anticoagulation by the direct thrombin inhibitor argatroban beginning immediately after the first dose of IVIG [5]. Due to its short plasma half-life time and the potential to be applied continuously, argatroban is superior to other non-heparin-derived anticoagulants in this severe condition with imminent profuse bleeding [5]. The efficacy was controlled by frequent measurement of the partial thromboplastin time (PTT) that should be elevated up to 1.5 times from normal (50–60 s) (Fig. 2). During the first night in our hospital, after application of 90 g IVIG, with a platelet count of 40/nl and a PTT of 50 s, the patient suffered two subsequent epileptic seizures as a consequence of a new left temporo-parietal intracranial hemorrhage found on CCT scan (Fig. 1c). The patient developed moderate aphasia and apraxia and antiepileptic drugs were started. After the second course of 90 g IVIG and successive normalization of the platelet count (Fig. 2), decline of the D-Dimers from 65.7 mg/L at presentation to 12.32 mg/L after 48 h (Fig. 2) and continuous application of i.v. agatroban with a mean PTT time of 42 s (Fig. 2), the patient improved to a slight aphasic syndrome. The transverse sinus successively recanalized as demonstrated on day 16 of treatment (Fig. 1b), as did the portal and mesenteric veins. Lactate serum levels stayed normal and the patient had no further abdominal discomfort. Antibody-mediated PF4-dependent platelet activation was confirmed in a blood sample taken before IVIG treatment as described [1] several days after the patient had recovered.
In conclusion, this case illustrates that immediate administration of high-dose IVIG and anticoagulation with direct thrombin inhibitor, avoiding application of platelet concentrates and initial administration of heparin, appears to be crucial in patients with life-threatening VITT even before the pathogenic PF4-heparin antibody is detected. Of the 16 published patients (11 in Germany and Austria, 5 in Norway) with unusual thrombotic events, 9 died of VITT [1, 2]. Only those patients who received high-dose IVIG close to the diagnosis of thrombocytopenia and thrombotic events with avoidance of platelet substitution further enhancing thrombus formation had a favorable prognosis in this otherwise devastating disease.

Declarations

Compliance with the ethical standards

All procedures performed in the case report were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Conflicts of interest

The authors declare that they have no conflict of interest.
Patient signed informed consent regarding publishing his data and CT/MRI scans.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

© Springer Medizin

Bis 11. April 2024 bestellen und im ersten Jahr 50 % sparen!

Neuer Inhalt

e.Med Neurologie & Psychiatrie

Kombi-Abonnement

Mit e.Med Neurologie & Psychiatrie erhalten Sie Zugang zu CME-Fortbildungen der Fachgebiete, den Premium-Inhalten der dazugehörigen Fachzeitschriften, inklusive einer gedruckten Zeitschrift Ihrer Wahl.

© Springer Medizin

Bis 11. April 2024 bestellen und im ersten Jahr 50 % sparen!

Weitere Produktempfehlungen anzeigen
Literatur
Metadaten
Titel
Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis
verfasst von
Tilmann Graf
Thomas Thiele
Randolf Klingebiel
Andreas Greinacher
Wolf-Rüdiger Schäbitz
Isabell Greeve
Publikationsdatum
22.05.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 12/2021
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-021-10599-2

Weitere Artikel der Ausgabe 12/2021

Journal of Neurology 12/2021 Zur Ausgabe

Passend zum Thema

ANZEIGE

IPD-Fallzahlen & Pneumokokken-Impfung bei Kindern in Deutschland

Das Niveau der postpandemischen Fallzahlen für invasive Pneumokokken-Erkrankungen (IPD) ist aus Sicht des Referenz-Zentrums für Streptokokken in Aachen alarmierend [1]. Wie sich die monatlichen IPD-Fallzahlen bei Kindern und Jugendlichen von Juli 2015 bis März 2023 entwickelt haben, lesen Sie hier.

ANZEIGE

HPV-Impfung: Auch für junge Erwachsene sinnvoll und wichtig

Auch nach dem 18. Lebensjahr kann eine HPV-Impfung sinnvoll und wichtig sein. Viele gesetzliche Krankenkassen übernehmen die Kosten auch zu einem späteren Zeitpunkt noch.

ANZEIGE

Impfstoffe – Krankheiten vorbeugen, bevor sie entstehen

Seit mehr als 130 Jahren entwickelt und produziert MSD Impfstoffe für alle Altersgruppen. Hier finden Sie nützliche Informationen und Praxismaterialien rund um das Thema Impfen.

MSD Sharp & Dohme GmbH